When is it right to reject an expensive new drug?
Articles on donanemab
Displaying all articles
Donanemab is only for use in the early stages of Alzheimer’s disease. And for now at least, it comes with a hefty price tag.
There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for Nice’s decision.
Donanemab will only be available via private healthcare.
Despite decades of starts and stops, new treatments and key genetic discoveries are giving researchers great hope for slowing or eventually preventing Alzheimer’s disease.
Late-stage trial results suggest the drug can slow cognitive decline by 35%.
Although Medicare has agreed to pay for Aduhelm, its coverage comes with restrictions.
Top contributors
-
Research Fellow in Neuroimmunology, UCL
-
Professor of Neurology and Neuroscience, University of Florida
-
Assistant Professor of Emergency Medicine, Albert Einstein College of Medicine
-
PhD Candidate, Neuroscience, University of Sheffield
-
Professor in Clinical Pharmacy, Aston University
-
Head of Clinical Services, Dementia Support Australia, & Associate Professor of Psychiatry, Monash University
-
Chair Professor, Health Policy and History, University of Liverpool
-
Senior Research Fellow, History of Health and Medicine, University of Liverpool